---
document_datetime: 2025-12-02 05:33:59
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/vemlidy.html
document_name: vemlidy.html
version: success
processing_time: 0.106307
conversion_datetime: 2025-12-28 02:40:47.589955
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Vemlidy

[RSS](/en/individual-human-medicine.xml/66802)

##### Authorised

This medicine is authorised for use in the European Union

tenofovir alafenamide Medicine Human Authorised

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [News on Vemlidy](#news-on)
- [More information on Vemlidy](#related-medicines)
- [Topics](#topics)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

This is a summary of the European public assessment report (EPAR) for Vemlidy. It explains how the Agency assessed the medicine to recommend its authorisation in the EU and its conditions of use. It is not intended to provide practical advice on how to use Vemlidy.

For practical information about using Vemlidy, patients should read the package leaflet or contact their doctor or pharmacist.

Expand section

Collapse section

## What is Vemlidy and what is it used for?

Vemlidy is an antiviral medicine for treating chronic (long-term) hepatitis B, an infectious disease that affects the liver.

This medicine is used in patients aged 12 years and older weighing at least 35 kg. It contains the active substance tenofovir alafenamide.

## How is Vemlidy used?

Vemlidy is available as 25 mg tablets which are taken by mouth (one tablet a day) with food.The patient will usually take their medicine for at least 6 to 12 months, and treatment may last several years.

Vemlidy can only be obtained with a prescription.

## How does Vemlidy work?

The active substance in Vemlidy, tenofovir alafenamide, works by stopping the hepatitis B virus in the liver from multiplying. It is converted in the body into its active compound tenofovir, which blocks the activity of reverse transcriptase, an enzyme made by the hepatitis B virus that allows it to reproduce itself in the cells it has infected.

## What benefits of Vemlidy have been shown in studies?

Vemlidy reduces levels of hepatitis B virus in most patients. In a study of 426 patients with 'e-antigen negative' chronic hepatitis, 94% of patients on Vemlidy had very low levels of viral DNA after 48 weeks of treatment. This result was similar to that in patients taking another form of tenofovir (tenofovir disoproxil fumarate) where 93% had very low viral DNA levels.

In a second study of 875 patients with 'e-antigen positive' chronic hepatitis, 64% of patients taking Vemlidy and 67% of those taking tenofovir disoproxil fumarate had very low levels of viral DNA after 48 weeks. These results suggest that the comparator medicine might be more effective in 'e-antigen positive' cases but differences seen are small.

The terms 'e-antigen positive' and 'e-antigen negative' refer to the presence or absence of e-antigen, a hepatitis B viral protein. If this protein is present, it means that the virus is multiplying rapidly and the viral load may be higher.

## What are the risks associated with Vemlidy?

The most common side effects with Vemlidy are headache (11% of patients), nausea (6% of patients) and tiredness (6% of patients). For the full list of side effects and restrictions see the package leaflet.

## Why is Vemlidy approved?

Vemlidy suppresses levels of hepatitis B virus in the body, and its effectiveness is comparable to that of another tenofovir medicine (tenofovir disoproxil fumarate). With regard to its risks, the side effects of Vemlidy are manageable. In addition, Vemlidy is effective at a lower dose than tenofovir disoproxil fumarate and may lead to reduced side effects in the kidneys and bones.

The Agency's Committee for Medicinal Products for Human Use (CHMP) therefore concluded that the benefits of Vemlidy outweigh its risks and recommended its approval in the EU.

## What measures are being taken to ensure the safe and effective use of Vemlidy?

Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Vemlidy have been included in the summary of product characteristics and the package leaflet.

## Other information about Vemlidy

The European Commission granted a marketing authorisation valid throughout the European Union for Vemlidy on 9 January 2017.

For more information about treatment with Vemlidy, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.

Vemlidy : EPAR - Summary for the public

Reference Number: EMA/788418/2016

English (EN) (78.83 KB - PDF)

**First published:** 10/03/2017

**Last updated:** 10/03/2017

[View](/en/documents/overview/vemlidy-epar-summary-public_en.pdf)

[Other languages (22)](#file-language-dropdown-567)

български (BG) (98.33 KB - PDF)

**First published:**

10/03/2017

**Last updated:**

10/03/2017

[View](/bg/documents/overview/vemlidy-epar-summary-public_bg.pdf)

español (ES) (71.95 KB - PDF)

**First published:**

10/03/2017

**Last updated:**

10/03/2017

[View](/es/documents/overview/vemlidy-epar-summary-public_es.pdf)

čeština (CS) (96.63 KB - PDF)

**First published:**

10/03/2017

**Last updated:**

10/03/2017

[View](/cs/documents/overview/vemlidy-epar-summary-public_cs.pdf)

dansk (DA) (71.65 KB - PDF)

**First published:**

10/03/2017

**Last updated:**

10/03/2017

[View](/da/documents/overview/vemlidy-epar-summary-public_da.pdf)

Deutsch (DE) (73.77 KB - PDF)

**First published:**

10/03/2017

**Last updated:**

10/03/2017

[View](/de/documents/overview/vemlidy-epar-summary-public_de.pdf)

eesti keel (ET) (71.01 KB - PDF)

**First published:**

10/03/2017

**Last updated:**

10/03/2017

[View](/et/documents/overview/vemlidy-epar-summary-public_et.pdf)

ελληνικά (EL) (101.24 KB - PDF)

**First published:**

10/03/2017

**Last updated:**

10/03/2017

[View](/el/documents/overview/vemlidy-epar-summary-public_el.pdf)

français (FR) (73.31 KB - PDF)

**First published:**

10/03/2017

**Last updated:**

10/03/2017

[View](/fr/documents/overview/vemlidy-epar-summary-public_fr.pdf)

hrvatski (HR) (92.25 KB - PDF)

**First published:**

10/03/2017

**Last updated:**

10/03/2017

[View](/hr/documents/overview/vemlidy-epar-summary-public_hr.pdf)

italiano (IT) (71.51 KB - PDF)

**First published:**

10/03/2017

**Last updated:**

10/03/2017

[View](/it/documents/overview/vemlidy-epar-summary-public_it.pdf)

latviešu valoda (LV) (94.89 KB - PDF)

**First published:**

10/03/2017

**Last updated:**

10/03/2017

[View](/lv/documents/overview/vemlidy-epar-summary-public_lv.pdf)

lietuvių kalba (LT) (95.38 KB - PDF)

**First published:**

10/03/2017

**Last updated:**

10/03/2017

[View](/lt/documents/overview/vemlidy-epar-summary-public_lt.pdf)

magyar (HU) (90.14 KB - PDF)

**First published:**

10/03/2017

**Last updated:**

10/03/2017

[View](/hu/documents/overview/vemlidy-epar-summary-public_hu.pdf)

Malti (MT) (97.26 KB - PDF)

**First published:**

10/03/2017

**Last updated:**

10/03/2017

[View](/mt/documents/overview/vemlidy-epar-summary-public_mt.pdf)

Nederlands (NL) (71.61 KB - PDF)

**First published:**

10/03/2017

**Last updated:**

10/03/2017

[View](/nl/documents/overview/vemlidy-epar-summary-public_nl.pdf)

polski (PL) (98.61 KB - PDF)

**First published:**

10/03/2017

**Last updated:**

10/03/2017

[View](/pl/documents/overview/vemlidy-epar-summary-public_pl.pdf)

português (PT) (72 KB - PDF)

**First published:**

10/03/2017

**Last updated:**

10/03/2017

[View](/pt/documents/overview/vemlidy-epar-summary-public_pt.pdf)

română (RO) (94.69 KB - PDF)

**First published:**

10/03/2017

**Last updated:**

10/03/2017

[View](/ro/documents/overview/vemlidy-epar-summary-public_ro.pdf)

slovenčina (SK) (96.57 KB - PDF)

**First published:**

10/03/2017

**Last updated:**

10/03/2017

[View](/sk/documents/overview/vemlidy-epar-summary-public_sk.pdf)

slovenščina (SL) (90.59 KB - PDF)

**First published:**

10/03/2017

**Last updated:**

10/03/2017

[View](/sl/documents/overview/vemlidy-epar-summary-public_sl.pdf)

Suomi (FI) (71.85 KB - PDF)

**First published:**

10/03/2017

**Last updated:**

10/03/2017

[View](/fi/documents/overview/vemlidy-epar-summary-public_fi.pdf)

svenska (SV) (71.53 KB - PDF)

**First published:**

10/03/2017

**Last updated:**

10/03/2017

[View](/sv/documents/overview/vemlidy-epar-summary-public_sv.pdf)

Vemlidy : EPAR - Risk management plan

English (EN) (1.6 MB - PDF)

**First published:** 18/08/2021

**Last updated:** 17/09/2024

[View](/en/documents/rmp-summary/vemlidy-epar-risk-management-plan_en.pdf)

## Product information

Vemlidy : EPAR - Product Information

English (EN) (595.53 KB - PDF)

**First published:** 10/03/2017

**Last updated:** 31/05/2023

[View](/en/documents/product-information/vemlidy-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-249)

български (BG) (760.83 KB - PDF)

**First published:**

10/03/2017

**Last updated:**

31/05/2023

[View](/bg/documents/product-information/vemlidy-epar-product-information_bg.pdf)

español (ES) (718.43 KB - PDF)

**First published:**

10/03/2017

**Last updated:**

31/05/2023

[View](/es/documents/product-information/vemlidy-epar-product-information_es.pdf)

čeština (CS) (714.27 KB - PDF)

**First published:**

10/03/2017

**Last updated:**

31/05/2023

[View](/cs/documents/product-information/vemlidy-epar-product-information_cs.pdf)

dansk (DA) (693 KB - PDF)

**First published:**

10/03/2017

**Last updated:**

31/05/2023

[View](/da/documents/product-information/vemlidy-epar-product-information_da.pdf)

Deutsch (DE) (719.52 KB - PDF)

**First published:**

10/03/2017

**Last updated:**

31/05/2023

[View](/de/documents/product-information/vemlidy-epar-product-information_de.pdf)

eesti keel (ET) (713.19 KB - PDF)

**First published:**

10/03/2017

**Last updated:**

31/05/2023

[View](/et/documents/product-information/vemlidy-epar-product-information_et.pdf)

ελληνικά (EL) (778.9 KB - PDF)

**First published:**

10/03/2017

**Last updated:**

31/05/2023

[View](/el/documents/product-information/vemlidy-epar-product-information_el.pdf)

français (FR) (712.26 KB - PDF)

**First published:**

10/03/2017

**Last updated:**

31/05/2023

[View](/fr/documents/product-information/vemlidy-epar-product-information_fr.pdf)

hrvatski (HR) (688.92 KB - PDF)

**First published:**

10/03/2017

**Last updated:**

31/05/2023

[View](/hr/documents/product-information/vemlidy-epar-product-information_hr.pdf)

íslenska (IS) (699.65 KB - PDF)

**First published:**

10/03/2017

**Last updated:**

31/05/2023

[View](/is/documents/product-information/vemlidy-epar-product-information_is.pdf)

italiano (IT) (709.69 KB - PDF)

**First published:**

10/03/2017

**Last updated:**

31/05/2023

[View](/it/documents/product-information/vemlidy-epar-product-information_it.pdf)

latviešu valoda (LV) (690.04 KB - PDF)

**First published:**

10/03/2017

**Last updated:**

31/05/2023

[View](/lv/documents/product-information/vemlidy-epar-product-information_lv.pdf)

lietuvių kalba (LT) (762.01 KB - PDF)

**First published:**

10/03/2017

**Last updated:**

31/05/2023

[View](/lt/documents/product-information/vemlidy-epar-product-information_lt.pdf)

magyar (HU) (788.84 KB - PDF)

**First published:**

10/03/2017

**Last updated:**

31/05/2023

[View](/hu/documents/product-information/vemlidy-epar-product-information_hu.pdf)

Malti (MT) (844.78 KB - PDF)

**First published:**

10/03/2017

**Last updated:**

31/05/2023

[View](/mt/documents/product-information/vemlidy-epar-product-information_mt.pdf)

Nederlands (NL) (699.87 KB - PDF)

**First published:**

10/03/2017

**Last updated:**

31/05/2023

[View](/nl/documents/product-information/vemlidy-epar-product-information_nl.pdf)

norsk (NO) (685.59 KB - PDF)

**First published:**

10/03/2017

**Last updated:**

31/05/2023

[View](/no/documents/product-information/vemlidy-epar-product-information_no.pdf)

polski (PL) (774.52 KB - PDF)

**First published:**

10/03/2017

**Last updated:**

31/05/2023

[View](/pl/documents/product-information/vemlidy-epar-product-information_pl.pdf)

português (PT) (702.67 KB - PDF)

**First published:**

10/03/2017

**Last updated:**

31/05/2023

[View](/pt/documents/product-information/vemlidy-epar-product-information_pt.pdf)

română (RO) (776.1 KB - PDF)

**First published:**

10/03/2017

**Last updated:**

31/05/2023

[View](/ro/documents/product-information/vemlidy-epar-product-information_ro.pdf)

slovenčina (SK) (781.23 KB - PDF)

**First published:**

10/03/2017

**Last updated:**

31/05/2023

[View](/sk/documents/product-information/vemlidy-epar-product-information_sk.pdf)

slovenščina (SL) (762.23 KB - PDF)

**First published:**

10/03/2017

**Last updated:**

31/05/2023

[View](/sl/documents/product-information/vemlidy-epar-product-information_sl.pdf)

Suomi (FI) (728.2 KB - PDF)

**First published:**

10/03/2017

**Last updated:**

31/05/2023

[View](/fi/documents/product-information/vemlidy-epar-product-information_fi.pdf)

svenska (SV) (689.61 KB - PDF)

**First published:**

10/03/2017

**Last updated:**

31/05/2023

[View](/sv/documents/product-information/vemlidy-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** II/0040 26/05/2023

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Vemlidy : EPAR - All Authorised presentations

English (EN) (47.91 KB - PDF)

**First published:** 10/03/2017

**Last updated:** 10/03/2017

[View](/en/documents/all-authorised-presentations/vemlidy-epar-all-authorised-presentations_en.pdf)

[Other languages (24)](#file-language-dropdown-74)

български (BG) (52.16 KB - PDF)

**First published:**

10/03/2017

**Last updated:**

10/03/2017

[View](/bg/documents/all-authorised-presentations/vemlidy-epar-all-authorised-presentations_bg.pdf)

español (ES) (49.75 KB - PDF)

**First published:**

10/03/2017

**Last updated:**

10/03/2017

[View](/es/documents/all-authorised-presentations/vemlidy-epar-all-authorised-presentations_es.pdf)

čeština (CS) (53.15 KB - PDF)

**First published:**

10/03/2017

**Last updated:**

10/03/2017

[View](/cs/documents/all-authorised-presentations/vemlidy-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (49.35 KB - PDF)

**First published:**

10/03/2017

**Last updated:**

10/03/2017

[View](/da/documents/all-authorised-presentations/vemlidy-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (49.4 KB - PDF)

**First published:**

10/03/2017

**Last updated:**

10/03/2017

[View](/de/documents/all-authorised-presentations/vemlidy-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (49.77 KB - PDF)

**First published:**

10/03/2017

**Last updated:**

10/03/2017

[View](/et/documents/all-authorised-presentations/vemlidy-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (54.15 KB - PDF)

**First published:**

10/03/2017

**Last updated:**

10/03/2017

[View](/el/documents/all-authorised-presentations/vemlidy-epar-all-authorised-presentations_el.pdf)

français (FR) (49.77 KB - PDF)

**First published:**

10/03/2017

**Last updated:**

10/03/2017

[View](/fr/documents/all-authorised-presentations/vemlidy-epar-all-authorised-presentations_fr.pdf)

hrvatski (HR) (51.34 KB - PDF)

**First published:**

10/03/2017

**Last updated:**

10/03/2017

[View](/hr/documents/all-authorised-presentations/vemlidy-epar-all-authorised-presentations_hr.pdf)

íslenska (IS) (50.12 KB - PDF)

**First published:**

10/03/2017

**Last updated:**

10/03/2017

[View](/is/documents/all-authorised-presentations/vemlidy-epar-all-authorised-presentations_is.pdf)

italiano (IT) (48.35 KB - PDF)

**First published:**

10/03/2017

**Last updated:**

10/03/2017

[View](/it/documents/all-authorised-presentations/vemlidy-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (51.05 KB - PDF)

**First published:**

10/03/2017

**Last updated:**

10/03/2017

[View](/lv/documents/all-authorised-presentations/vemlidy-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (52.58 KB - PDF)

**First published:**

10/03/2017

**Last updated:**

10/03/2017

[View](/lt/documents/all-authorised-presentations/vemlidy-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (50.22 KB - PDF)

**First published:**

10/03/2017

**Last updated:**

10/03/2017

[View](/hu/documents/all-authorised-presentations/vemlidy-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (51.5 KB - PDF)

**First published:**

10/03/2017

**Last updated:**

10/03/2017

[View](/mt/documents/all-authorised-presentations/vemlidy-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (48.61 KB - PDF)

**First published:**

10/03/2017

**Last updated:**

10/03/2017

[View](/nl/documents/all-authorised-presentations/vemlidy-epar-all-authorised-presentations_nl.pdf)

norsk (NO) (48.7 KB - PDF)

**First published:**

10/03/2017

**Last updated:**

10/03/2017

[View](/no/documents/all-authorised-presentations/vemlidy-epar-all-authorised-presentations_no.pdf)

polski (PL) (50.41 KB - PDF)

**First published:**

10/03/2017

**Last updated:**

10/03/2017

[View](/pl/documents/all-authorised-presentations/vemlidy-epar-all-authorised-presentations_pl.pdf)

português (PT) (49.55 KB - PDF)

**First published:**

10/03/2017

**Last updated:**

10/03/2017

[View](/pt/documents/all-authorised-presentations/vemlidy-epar-all-authorised-presentations_pt.pdf)

română (RO) (50.7 KB - PDF)

**First published:**

10/03/2017

**Last updated:**

10/03/2017

[View](/ro/documents/all-authorised-presentations/vemlidy-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (53.4 KB - PDF)

**First published:**

10/03/2017

**Last updated:**

10/03/2017

[View](/sk/documents/all-authorised-presentations/vemlidy-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (51.76 KB - PDF)

**First published:**

10/03/2017

**Last updated:**

10/03/2017

[View](/sl/documents/all-authorised-presentations/vemlidy-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (48.89 KB - PDF)

**First published:**

10/03/2017

**Last updated:**

10/03/2017

[View](/fi/documents/all-authorised-presentations/vemlidy-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (48.54 KB - PDF)

**First published:**

10/03/2017

**Last updated:**

10/03/2017

[View](/sv/documents/all-authorised-presentations/vemlidy-epar-all-authorised-presentations_sv.pdf)

## Product details

Name of medicine Vemlidy Active substance tenofovir alafenamide fumarate International non-proprietary name (INN) or common name tenofovir alafenamide Therapeutic area (MeSH) Hepatitis B Anatomical therapeutic chemical (ATC) code J05AF13

### Pharmacotherapeutic group

Antivirals for systemic use

### Therapeutic indication

Vemlidy is indicated for the treatment of chronic hepatitis B (CHB) in adults and paediatric patients 6 years of age and older weighing at least 25 kg (see section 5.1).

## Authorisation details

EMA product number EMEA/H/C/004169 Marketing authorisation holder

Gilead Sciences Ireland UC

IDA Business &amp; Technology Park

Opinion adopted 10/11/2016 Marketing authorisation issued 09/01/2017 Revision 17

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

Vemlidy : EPAR - Procedural steps taken and scientific information after authorisation

English (EN) (253.57 KB - PDF)

**First published:** 19/12/2017

**Last updated:** 17/09/2024

[View](/en/documents/procedural-steps-after/vemlidy-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf)

Vemlidy-H-C-004169-II-0040 : EPAR - Assessment report - Variation

Adopted

Reference Number: EMA/CHMP/155784/2023

English (EN) (3.52 MB - PDF)

**First published:** 31/05/2023

[View](/en/documents/variation-report/vemlidy-h-c-004169-ii-0040-epar-assessment-report-variation_en.pdf)

CHMP post-authorisation summary of positive opinion for Vemlidy (II-40)

Adopted

Reference Number: EMA/CHMP/155745/2023

English (EN) (124.16 KB - PDF)

**First published:** 26/04/2023

[View](/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-vemlidy-ii-40_en.pdf)

Vemlidy-H-C-PSUSA-00010575-202111 : EPAR - Scientific conclusions and grounds for the variation to the terms of the marketing authorisation

Reference Number: EMA/725885/2022

English (EN) (139.35 KB - PDF)

**First published:** 05/09/2022

[View](/en/documents/scientific-conclusion/vemlidy-h-c-psusa-00010575-202111-epar-scientific-conclusions-and-grounds-variation-terms-marketing-authorisation_en.pdf)

Vemlidy-H-C-PSUSA-00010575-201911 : EPAR - Scientific conclusions and grounds for the variation to the terms of the marketing authorisation(

Reference Number: EMA/322640/2020

English (EN) (100.83 KB - PDF)

**First published:** 14/09/2020

[View](/en/documents/scientific-conclusion/vemlidy-h-c-psusa-00010575-201911-epar-scientific-conclusions-and-grounds-variation-terms-marketing-authorisation_en.pdf)

## Initial marketing authorisation documents

Vemlidy : EPAR - Public assessment report

Adopted

Reference Number: EMA/793580/2016

English (EN) (5.04 MB - PDF)

**First published:** 10/03/2017

**Last updated:** 10/03/2017

[View](/en/documents/assessment-report/vemlidy-epar-public-assessment-report_en.pdf)

CHMP summary of positive opinion for Vemlidy

Adopted

Reference Number: EMA/704543/2016

English (EN) (73.79 KB - PDF)

**First published:** 11/11/2016

**Last updated:** 11/11/2016

[View](/en/documents/smop-initial/chmp-summary-positive-opinion-vemlidy_en.pdf)

#### News on Vemlidy

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 24 - 26 April 2023](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-24-26-april-2023) 26/04/2023

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 7-10 November 2016](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-7-10-november-2016) 11/11/2016

- [Clinical data](https://clinicaldata.ema.europa.eu/web/cdp/home?p_p_id=cdpdossierviewportlet_WAR_cdpdossierviewportlet=0=maximized=view=column-3=2=EMEAHC0041690000) (initial marketing authorisation)

#### More information on Vemlidy

- [EMEA-001584-PIP01-13-M07 - paediatric investigation plan](/en/medicines/human/paediatric-investigation-plans/emea-001584-pip01-13-m07)

#### Topics

- [Medicines](https://www.ema.europa.eu/en/search?f%5B0%5D=ema_search_topics%3A61)

**This page was last updated on** 17/09/2024

## Share this page

[Back to top](#main-content)